---
title: "These Analysts Increase Their Forecasts On Immunovant After Q4 Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287250728.md"
description: "Immunovant (NASDAQ:IMVT) reported a Q4 loss of 73 cents/share, missing estimates of 60 cents. R&D expenses rose to $142.3 million. Analysts adjusted price targets, with HC Wainwright raising it from $35 to $40 and B of A Securities from $32 to $43. Immunovant shares fell 5% to $33.76."
datetime: "2026-05-21T16:07:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287250728.md)
  - [en](https://longbridge.com/en/news/287250728.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287250728.md)
---

# These Analysts Increase Their Forecasts On Immunovant After Q4 Results

**Immunovant Inc** (NASDAQ:IMVT) on Wednesday posted a wider fourth‑quarter loss than analysts expected.

The company reported a quarterly loss of 73 cents per share, falling short of the 60 cents consensus estimate.

Research and development spending rose to $142.3 million for the quarter, driven by IMVT‑1402 trial activity and $39 million in costs tied to discontinuing batoclimab. Non‑GAAP R&D expenses for the full fiscal year reached $426.9 million, up from $333.9 million the prior year.

Immunovant shares fell 5% to trade at $33.76 on Thursday.

These analysts made changes to their price targets on Immunovant following earnings announcement.

-   HC Wainwright & Co. analyst Douglas Tsao maintained Immunovant with a Buy and raised the price target from $35 to $40.
-   B of A Securities analyst Jason Gerberry maintained the stock with a Buy and raised the price target from $32 to $43.

**Considering buying IMVT stock? Here’s what analysts think:**

_Photo via Shutterstock_

### Related Stocks

- [IMVT.US](https://longbridge.com/en/quote/IMVT.US.md)

## Related News & Research

- [Assessing Immunovant (IMVT) Valuation After Strong IMVT-1402 Data And Refocused Pipeline Strategy](https://longbridge.com/en/news/287221923.md)
- [Immunovant Posts Wider FY26 Loss, Advances IMVT-1402 Pipeline; Stock Up](https://longbridge.com/en/news/287065251.md)
- [Immunovant reports $147.9M quarterly net loss, $902.1M cash as of Mar 31, 2026](https://longbridge.com/en/news/287056202.md)
- [Immunovant (NASDAQ:IMVT) Stock Price Down 6.4% on Disappointing Earnings](https://longbridge.com/en/news/287244359.md)
- [Walmart Stock: Here’s Why Analysts Are Raising Price Targets Before Q1 Earnings.](https://longbridge.com/en/news/286950969.md)